Dermata Therapeutics, Inc. announces a private placement priced at-the-market under Nasdaq rules, with gross proceeds of up to $12.4 million, including potential additional proceeds from warrants.
The offering includes 2,022,062 shares of common stock, series C warrants, and short-term series D warrants priced at $2.04 per share.
Company insiders, including executives, are participating in the offering at the same purchase price as other investors.
Gross Proceeds
Expected to be approximately $4.1 million, with potential additional gross proceeds of up to $8.3 million from warrants.
Offering Closing
Expected to occur around December 29, 2025, subject to customary closing conditions.
Use of Proceeds
Intended for general corporate purposes, including consumer research, product launches, investments, and working capital.
- The offering is expected to provide Dermata Therapeutics with significant funds for its development and growth initiatives.
- Company executives' participation in the offering demonstrates confidence in the company's future prospects.
Dermata Therapeutics' private placement marks a strategic move to secure funding for future endeavors and highlights investor confidence in the company's direction.